Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Karastaneva, A; Gasparella, P; Tschauner, S; Crazzolara, R; Kropshofer, G; Modl, M; Pfleger, A; Burmas, A; Pocivalnik, M; Ulreich, R; Zenz, W; Schwinger, W; Beqo, BP; Urban, C; Haxhija, EQ; Lackner, H; Benesch, M.
Indications and Limitations of Sirolimus in the Treatment of Vascular Anomalies-Insights From a Retrospective Case Series.
Front Pediatr. 2022; 10:857436
Doi: 10.3389/fped.2022.857436
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Gasparella Paolo
- Karastaneva Anna
- Co-authors Med Uni Graz
- Benesch Martin
- Beqo Besiana
- Burmas Ante
- Haxhija Emir
- Lackner Herwig
- Modl Manfred
- Pfleger Andreas
- Ribitsch Mirjam
- Schwinger Wolfgang
- Tschauner Sebastian
- Ulreich Raphael
- Urban Ernst-Christian
- Zenz Werner
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background: Despite recent developments, the role of sirolimus in the heterogeneous spectrum of vascular anomalies is yet to be defined, in terms of indication, dosage, and therapy duration, recognizing both its potential and limitations. Methods: We retrospectively analyzed 16 children with vascular anomalies treated with sirolimus in two pediatric centers between 2014 and 2020 [male: n = 7, the median age at diagnosis: 4.6 months (range, 0-281.4)]. In addition, repetitive volumetric analyses of the vascular anomalies were performed when possible (11 cases). Results: Ten patients were diagnosed with vascular malformations and 6 with vascular tumors. The mean therapy duration was 27.2 months (range, 3.5-65). The mean sirolimus level was 8.52 ng/ml (range, 5.38-12.88). All patients except one with central conducting lymphatic anomaly responded to sirolimus, with the most noticeable volume reduction in the first 4-6 months. Additional administration of vincristine was needed in five patients with kaposiform hemangioendothelioma and yielded a response, even in cases, refractory to sirolimus monotherapy. As a single agent, sirolimus led to impressive improvement in a patient with another vascular tumor-advanced epithelioid hemangioendothelioma. Complicated vascular malformations required long-term sirolimus therapy. Side effects of sirolimus included mucositis and laboratory abnormalities. No major infectious episodes were recorded. An infant with COVID-19, diagnosed while on sirolimus therapy, presented with a mild course. Conclusion: In the current series, we reported limitations of sirolimus as monotherapy, addressing the need to redefine its indications, and explore combination regimens and multimodal treatment strategies. Tools for objective evaluation of response trends over time could serve as a basis for the establishment of future therapeutic algorithms.
- Find related publications in this database (Keywords)
- sirolimus
- vascular anomalies
- vincristine
- Kasabach-Merritt phenomenon
- central conducting lymphatic anomaly (CCLA)
- epithelioid hemangioendothelioma (EHE)
- COVID-19